People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Caladrius Biosciences, Inc. | — | Biotechnology | Series B | $87.4M | $777.5M | 2009 |
| Cryoport, Inc. | — | Biotechnology | Series B | $52.9M | $992.2M | 2016 |
| MetaStat, Inc. | — | Biotechnology | Series A | $39.2M | $122.2M | 2014 |
| Seelos Therapeutics, Inc. | — | Biotechnology | Series A | $27.7M | $5.9M | 2010 |
| ComSovereign Holding Corp. | — | Other Technology | Series A | $23.3M | $39.3M | 2020 |
| Biovie Inc. | — | Biotechnology | Series A | $10.5M | $81.2M | 2022 |
| Titan Environmental Solutions Inc. | — | Other | Series A | $4.4M | $20.7M | 2023 |
| ComSovereign Corp. | — | Other Technology | Pre-Seed | $200K | $8.5M | 2019 |
Richard J. Berman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard J. Berman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.